Compounded tirzepatide with pyridoxine (vitamin B6) is a pharmacy-prepared formulation combining tirzepatide — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — with pyridoxine in a single injectable product. It is prepared for individual patients under a prescription by licensed compounding pharmacies and is not an FDA-approved drug.
For clinics running metabolic and weight-management programs, this formulation sits at the center of the most consequential compounding-policy shift of the past two years. It is also the #1 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026 — which makes understanding its post-shortage regulatory posture essential for any prescriber who orders it.
What Tirzepatide with B6 Is
Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors. FDA-approved versions of tirzepatide exist: Mounjaro (approved in 2022 for type 2 diabetes) and Zepbound (approved in 2023 for chronic weight management in adults meeting specified criteria). Those approvals — and the labeling that accompanies them — apply to the branded products, not to compounded formulations.
Pyridoxine hydrochloride (vitamin B6) is a water-soluble vitamin that, in this context, is added as a secondary ingredient to a compounded tirzepatide preparation. The combination exists only as a compounded product; no FDA-approved drug pairs tirzepatide with pyridoxine.
Two points deserve emphasis for prescribers evaluating this category:
- Compounded tirzepatide with B6 has not undergone FDA review for safety, effectiveness, or quality. FDA has stated that the safety and effectiveness of combining GLP-1 class drugs with additional ingredients such as pyridoxine has not been established.
- A compounded preparation is not interchangeable with, or a generic of, the branded tirzepatide products. It is a distinct, patient-specific preparation whose quality depends on the pharmacy that makes it.
How Providers Use It in Practice
Clinics that order compounded tirzepatide formulations are concentrated in weight-management, metabolic health, and longevity practices, with some endocrinology and primary-care practices also represented. In these settings, some providers prescribe compounded tirzepatide with B6 for patients for whom they have documented a specific clinical reason that an FDA-approved tirzepatide product does not meet the patient's needs — which, as discussed below, is now the legal linchpin of the entire category.
The practical appeal for clinics has historically included vial-based dispensing (as opposed to fixed-dose autoinjector pens), formulation flexibility, and the ability to incorporate an additive the prescriber deems clinically necessary for a particular patient. Whether any of those attributes constitutes a legitimate, documentable clinical difference for a given patient is a determination the prescriber — not the pharmacy, and not a marketing department — is responsible for making.
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed prescribers to licensed 503A and 503B compounding pharmacies; the prescribing decision and its clinical justification remain entirely with the provider.
Forms and Combinations Available Through Compounding
Compounding pharmacies have historically prepared tirzepatide in several patient-specific configurations:
- Injectable solution with pyridoxine (B6) — the subject of this guide, typically dispensed as a multi-dose vial for subcutaneous administration.
- Injectable tirzepatide without additives — a base formulation, which after the shortage resolution faces the most direct "essentially a copy" exposure.
- Alternate additive combinations — such as tirzepatide with cyanocobalamin (B12) or tirzepatide with L-carnitine, each raising the same individualized-justification questions as the B6 version.
- Oral presentations — some pharmacies prepare tirzepatide/pyridoxine in capsule form; the same individualized-justification analysis applies regardless of route.
The traditional rationale for compounding — patient-specific customization that a manufactured product cannot provide — is the only rationale that survives in the post-shortage environment. A formulation change made for a population of patients, or made primarily to differentiate a product commercially, does not fit that rationale. FDA has specifically noted that some compounders incorporate ingredients such as pyridoxine, cyanocobalamin, levocarnitine, and NAD into GLP-1 class preparations, and has questioned the clinical basis for doing so on a blanket scale. No dosing or titration information is presented here; strength and regimen are individualized clinical decisions between the prescriber and the compounding pharmacist.
Regulatory Status and Provider Considerations
The shortage resolution changed the legal foundation
During the tirzepatide shortage, compounded versions were broadly permissible because shortage-listed drugs are exempt from the "essentially a copy" restrictions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. That era is over. FDA determined in a declaratory order dated December 19, 2024 that the tirzepatide shortage was resolved, and the agency's enforcement-discretion transition periods expired in early 2025 — after which compounding tirzepatide products that are essentially copies of Mounjaro or Zepbound returned to being restricted (as of July 2026, this remains the operative framework).
What "essentially a copy" means for a B6 combination
For a 503A pharmacy, a compounded drug is not treated as an essential copy if the prescriber determines — and documents on the prescription — that a change made for an identified individual patient produces a significant clinical difference for that patient compared with the commercially available product. Applied to tirzepatide with B6, that means:
- The presence of pyridoxine does not, by itself, take the preparation outside the essential-copy analysis. FDA has publicly questioned blanket additive rationales for GLP-1 class compounds.
- The documented, patient-specific clinical justification is the prescriber's responsibility. A pharmacy cannot supply that justification for the prescriber, and a pre-printed or templated statement applied across a patient panel is unlikely to satisfy the individualized standard.
- Prescribers should be prepared to articulate, in the record, why this patient needs this modification — and why an FDA-approved tirzepatide product cannot meet that need.
For 503B outsourcing facilities, the essential-copy analysis is stricter still, and the bulk-substance pathway is now under direct challenge.
The 2026 proposed 503B bulks-list exclusion
On May 1, 2026, FDA published a Federal Register notice proposing to exclude tirzepatide — along with semaglutide and liraglutide — from the 503B bulks list, based on the agency's proposed finding that there is no clinical need for outsourcing facilities to compound these drugs from bulk drug substances. Because 503B facilities generally may compound from bulk substances only when the substance is on the bulks list or the drug is in shortage, a finalized exclusion would materially curtail 503B production of compounded tirzepatide in any form, additive or not. FDA extended the public comment period to July 30, 2026, and no final determination has issued as of this writing. Clinics that rely on 503B-sourced tirzepatide formulations should be actively planning for the possibility that this supply channel narrows or closes.
Investigational agents are a different category entirely
Providers frequently ask whether newer investigational incretin agents, such as retatrutide, can be compounded the way tirzepatide has been; they cannot — an investigational drug with no FDA approval is not eligible for compounding at all. For the full picture, see the retatrutide regulatory status fact check.
Practical compliance posture for prescribers, as of July 2026
- Document individualized clinical need on every prescription for a compounded tirzepatide product, in your own clinical language, specific to the patient.
- Know which pathway your pharmacy operates under (503A vs. 503B) and how the pending 503B bulks proposal could affect continuity of care.
- Do not represent compounded tirzepatide with B6 to patients or in marketing as FDA-approved, or as equivalent to Mounjaro or Zepbound. It is neither.
- Monitor FDA's compounding communications; this category is moving quickly, and enforcement priorities have already shifted once since 2024.
Sourcing and Quality: What to Ask a Compounding Pharmacy
FDA has separately alerted providers to dosing errors and quality problems associated with some compounded injectable GLP-1 class products, which makes pharmacy diligence a clinical-risk issue, not just a compliance one. Before ordering, prescribers should ask:
- API source and documentation. Where is the tirzepatide active pharmaceutical ingredient sourced, and will the pharmacy provide Certificates of Analysis for both the tirzepatide API and the pyridoxine? Is the API the base form used in the approved drugs, or a salt form (FDA has flagged unapproved salt forms in the GLP-1 compounding market)?
- Compounding standards. Does the pharmacy document compliance with USP <797> for sterile compounding (and USP <795>/<800> where applicable)? For a 503B facility, ask about its most recent FDA inspection history.
- Potency and sterility testing. Is each batch tested for potency, sterility, and endotoxin, and are results available to the prescriber?
- Beyond-use dating. What beyond-use date is assigned, and on what stability data is it based — particularly relevant for a multi-ingredient preparation, since additive combinations can behave differently from single-ingredient solutions?
- Labeling clarity. Are concentration and total container volume labeled in a way that minimizes the dose-calculation ambiguity FDA has warned about with vial-based GLP-1 products?
- State licensure. Is the pharmacy licensed in the patient's state of residence, and does it hold any required nonresident pharmacy licenses?
Frequently Asked Questions
Is compounded tirzepatide with B6 FDA-approved?
No. FDA-approved tirzepatide products exist (Mounjaro and Zepbound), but no compounded tirzepatide formulation — with or without pyridoxine — is FDA-approved, and none has been evaluated by FDA for safety, effectiveness, or quality.
Can 503A pharmacies still compound tirzepatide now that the shortage is resolved?
Only within the "essentially a copy" limits of section 503A. As of July 2026, that generally requires a prescriber-documented determination that a change made for an identified individual patient produces a significant clinical difference relative to the commercially available product. Routine, undifferentiated compounding of tirzepatide is no longer supported by the shortage exemption.
Does adding B6 automatically make the product legally distinct from the branded drugs?
No. FDA has questioned blanket clinical rationales for additives in GLP-1 class compounds. The additive must be tied to a documented, patient-specific clinical need articulated by the prescriber; the ingredient's mere presence does not settle the essential-copy question.
How would the 2026 503B bulks proposal affect my clinic?
If FDA finalizes the proposed exclusion of tirzepatide from the 503B bulks list, outsourcing facilities would generally lose the ability to compound tirzepatide from bulk substance outside of a future shortage. Clinics sourcing from 503B facilities should discuss contingency plans with their pharmacy partners now; the comment period closes July 30, 2026.
What should be in my chart to support a compounded tirzepatide prescription?
A patient-specific clinical rationale, in the prescriber's own words, explaining why the FDA-approved products do not meet the individual patient's needs and why the compounded modification does. Documentation should live in both the medical record and, for 503A dispensing, on the prescription itself.
Related Reading
- See where tirzepatide with B6 ranks among the most-prescribed compounded medications on ScriptLinkRx.
- Compounded semaglutide with B6 — the parallel formulation facing the same post-shortage framework.
- Compounded tirzepatide with B12 — how the cyanocobalamin variant compares.
- Compounded tirzepatide with L-carnitine — additive considerations for the levocarnitine combination.
Sources
- FDA, Declaratory Order: Resolution of Shortages of Tirzepatide Injection (December 19, 2024)
- FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (2026)
- Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (May 1, 2026)
- Federal Register, 503B Bulks List Notice; Extension of Comment Period (June 26, 2026)
- FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
